ClinicalTrials.gg
CompletedNCT07951450Updated Nov 20, 2026

Comparing Three Treatments for Biceps Tendon Pain in the Shoulder

An interventional study of Subacromial Triamcinolone Acetonide and Bupivacaine and Naproxen Sodium in Long Head of the Biceps Tendinopathy, sponsored by Fatih Turkmensoy. Completed at 1 site in Turkey (Türkiye). Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-11-20.

Sponsored by Fatih Turkmensoy · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Registered 5 years 7 months after the study started (first participant enrolled Apr 2021, registered Nov 2026).
Updated Nov 20, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
75
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 24 studies in Tendinopathy with a site in Turkey — 6 open to participants now, 7 under way, none of them phase 3. Tendinopathy · Turkey.

Enrollment
Largest of 19
75 · median 42
Started
2021
the only one that year
No phase
19 of 24
5 open now
Registered
24th of 24
by date
Lead sponsor
1 of 24
Fatih Turkmensoy

Among the 24 studies in Tendinopathy with a site in Turkey, this one has the largest enrollment of the 19 interventional ones that give a count, is the only one that started in 2021, is one of 19 with no phase, and was the 24th registered.

Tendinopathy

399 studies on the registry are indexed under Tendinopathy; 77 are open to participants now.

Browse Tendinopathy studies →

Open to participants now

6 of the 24 studies in Tendinopathy with a site in Turkey are open now. Recruiting first, the newest first:

1 more — sign in →

All 6 open studies →

A study can be open while its sites in Turkey have not opened yet or have stopped. Only those recruiting at a site in Turkey →

Who these studies take

Of the 46 Tendinopathy studies recruiting now, 17 (37%) set no upper age limit and 22 (48%) stop at 75 or younger; 1 takes children under 18; 7 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 24 studies in Tendinopathy with a site in Turkey, or all of them as a file.
02

Study summary

This study compared three treatments for persistent shoulder pain related to the long head of the biceps tendon. This tendon connects the biceps muscle to the shoulder.

Seventy-five participants were randomly assigned to one of three groups: a steroid injection into the space above the shoulder tendons (the subacromial space), an oral anti-inflammatory medicine (naproxen sodium) taken daily for 28 days, or an ultrasound-guided steroid injection into the sheath around the biceps tendon.

The main outcome was the diameter of the biceps tendon measured by ultrasound four weeks after treatment started. The study also assessed shoulder pain, shoulder function, and difficulty using the arm at four weeks.

03

Conditions studied

  • Long Head of the Biceps Tendinopathy

Browse trials for

Keywords

  • Shoulder Pain Tendon Diameter Subacromial Injection Ultrasound-Guided Tendon Sheath Injection Naproxen Sodium
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

-

Exclusion Criteria:Inclusion Criteria:

  • Age 18 to 65 years, inclusive.
  • Persistent shoulder pain for at least 3 months, localized to the long head of the biceps tendon.
  • Positive Speed test and negative shoulder impingement tests.
  • Intact continuity of the long head of the biceps tendon on magnetic resonance imaging (MRI).
  • No prior treatment or rehabilitation for the presenting shoulder condition.
  • Patients with a partial-thickness or interstitial supraspinatus tear were eligible if it was not and the pain was isolated to the long head of the biceps tendon.

Exclusion criteria

Exclusion Criteria:

  • History of major shoulder trauma or fracture of the clavicle, scapula, or humerus.
  • Bilateral shoulder pain.
  • Systemic disease associated with joint effusion, such as rheumatoid arthritis.
  • Metabolic disease, such as diabetes mellitus.
  • Anatomical variant of the long head of the biceps tendon.
  • Partial or complete tear of the long head of the biceps tendon.
  • Major or full-thickness rotator cuff tear.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
75 participants (actual)

Study arms

  • Experimental
    Landmark-Guided Subacromial Corticosteroid Injection

    Participants received a single subacromial injection of triamcinolone acetonide and bupivacaine using anatomical landmarks.

    Drug: Subacromial Triamcinolone Acetonide and Bupivacaine

  • Experimental
    Oral Naproxen Sodium

    Participants received oral naproxen sodium once daily for 28 days

    Drug: Naproxen Sodium

  • Experimental
    Ultrasound-Guided Biceps Tendon Sheath Corticosteroid Injection

    Participants received a single ultrasound-guided injection of triamcinolone acetonide and bupivacaine into the sheath of the long head of the biceps tendon.

    Drug: Ultrasound-Guided Tendon Sheath Triamcinolone Acetonide and Bupivacaine

Interventions

  • DrugSubacromial Triamcinolone Acetonide and Bupivacaine

    A single landmark-guided subacromial injection of 1 mL triamcinolone acetonide (40 mg) combined with 9 mL of 0.5% bupivacaine.

  • DrugNaproxenStudies of NaproxenNaproxen pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Naproxen sodium 750 mg was taken orally once daily for 28 days.

  • DrugUltrasound-Guided Tendon Sheath Triamcinolone Acetonide and Bupivacaine

    A single ultrasound-guided injection of 1 mL triamcinolone acetonide (40 mg) combined with 9 mL of 0.5% bupivacaine into the sheath of the long head of the biceps tendon.

06

What researchers measure

Primary outcomes

  1. Long Head of the Biceps Tendon Diameter at Week 4

    The diameter of the long head of the biceps tendon was measured by ultrasound at its widest point within the bicipital groove. Two radiologists performed the measurements and determined the final value by consensus.

    Time frame: 4 weeks after treatment initiation

Secondary outcomes

  1. QuickDASH Total Score at Week 4

    The QuickDASH measures patient-reported upper-extremity disability and symptoms. Scores range from 0 to 100, with higher scores indicating greater disability.

    Time frame: 4 weeks after treatment initiation

  2. Constant Score at Week 4

    The Constant score measures shoulder function. Scores range from 0 to 100, with higher scores indicating better shoulder function.

    Time frame: 4 weeks after treatment initiation

  3. Shoulder Pain Intensity on a Visual Analog Scale at Week 4

    Participants rated their shoulder pain on a visual analog scale from 0 to 10, with higher scores indicating greater pain intensity.

    Time frame: 4 weeks after treatment initiation

07

Study locations

1 site
  • Bursa Yuksek Ihtisas Training and Research Hospital
    Bursa, Bursa, Turkey (Türkiye)
08

References and documents

Individual participant data

Plan to share: No — There is no plan to share individual participant data with other researchers.

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2021 to primary completion in Sep 2024, 41 months.

Of 174 non-industry interventional studies with no phase under Tendinopathy, half reached primary completion within 20 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 38. This study's 41 months is above that.

Counting every sponsor, half of 183 studies reached it within 20 months; a quarter within 7 and three quarters within 37.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 16, 2026
First posted
Nov 20, 2026
StartActual
Apr 1, 2021
Primary completionActual
Sep 27, 2024
CompletionActual
Sep 27, 2024
Last update
Nov 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 20, 2026
Show all 1 update
  1. Nov 20, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07951450
Lead sponsor
Fatih Turkmensoy
Responsible party
Fatih Turkmensoy (Principal Investigator, Bursa Yuksek Ihtisas Training and Research Hospital) — Sponsor-investigator
First posted
Nov 20, 2026
Start date
Apr 1, 2021
Primary completion
Sep 27, 2024
Completion
Sep 27, 2024
Last update
Nov 20, 2026

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Naproxen

Start the discussion